These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

842 related items for PubMed ID: 21353113

  • 1. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [Abstract] [Full Text] [Related]

  • 2. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [Abstract] [Full Text] [Related]

  • 3. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.
    J Clin Oncol; 2011 May 20; 29(15):1987-96. PubMed ID: 21483003
    [Abstract] [Full Text] [Related]

  • 4. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
    Gidwani R, Khan ZM, Fenaux P, Beach CL, Pashos CL.
    J Med Econ; 2012 May 20; 15(1):145-54. PubMed ID: 21988635
    [Abstract] [Full Text] [Related]

  • 5. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
    Tomonaga M, Kamae I.
    Rinsho Ketsueki; 2012 Mar 20; 53(3):310-7. PubMed ID: 22499047
    [Abstract] [Full Text] [Related]

  • 6. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
    Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, Saba H.
    Cancer; 2006 Apr 15; 106(8):1794-803. PubMed ID: 16532500
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z.
    Clin Ther; 2013 Jan 15; 35(1):54-65. PubMed ID: 23328269
    [Abstract] [Full Text] [Related]

  • 8. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, Mujica Mota RE.
    Pharmacoeconomics; 2017 Mar 15; 35(3):363-373. PubMed ID: 27752999
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M, Jiang Q, Xie Y.
    Clin Lymphoma Myeloma Leuk; 2015 Jan 15; 15(1):22-8. PubMed ID: 25042977
    [Abstract] [Full Text] [Related]

  • 11. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH.
    Leukemia; 2013 Sep 15; 27(9):1803-12. PubMed ID: 23757301
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(5):759-66. PubMed ID: 17564707
    [Abstract] [Full Text] [Related]

  • 13. Myelodysplastic syndromes: health care management considerations.
    Kogan AJ, Dunn JD.
    Manag Care; 2009 Nov 15; 18(11 Suppl 9):25-8; discussion 28-9. PubMed ID: 20085114
    [Abstract] [Full Text] [Related]

  • 14. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP.
    Eur J Haematol; 2008 Dec 15; 81(6):467-74. PubMed ID: 18754857
    [Abstract] [Full Text] [Related]

  • 15. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
    Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.
    Ann Hematol; 2015 Dec 15; 94(12):2003-13. PubMed ID: 26400023
    [Abstract] [Full Text] [Related]

  • 16. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.
    Cancer; 2007 Jan 15; 109(2):265-73. PubMed ID: 17133405
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
    Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M.
    Value Health; 2012 Jan 15; 15(1):65-71. PubMed ID: 22264973
    [Abstract] [Full Text] [Related]

  • 18. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL, Cosler LE, Ferro SA, Lyman GH.
    J Natl Compr Canc Netw; 2008 Oct 15; 6(9):942-53. PubMed ID: 18926103
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.
    JAMA Oncol; 2015 Nov 15; 1(8):1120-7. PubMed ID: 26355382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.